Prevalence of valvular heart disease
Prevalence of valvular heart disease Valvular heart disease (VHD) encompasses a range of conditions involving damage or defects of one or more of the heart’s four valves: the aortic, mitral, pulmonary, and tricuspid valves. These valves are essential for maintaining unidirectional blood flow through the heart and into the arteries. When they malfunction—either by narrowing (stenosis), leaking (regurgitation), or being abnormally thickened—they can impair cardiac efficiency and lead to significant health issues.
The prevalence of valvular heart disease varies globally, influenced by factors such as age, geographic location, and underlying health conditions. As populations age, the incidence of VHD, particularly degenerative types such as calcific aortic stenosis and mitral regurgitation, has increased markedly. Studies indicate that in developed countries, up to 2-3% of individuals over 65 exhibit some form of clinically significant valvular abnormality. In contrast, rheumatic heart disease—a common cause in developing countries—remains a major contributor to VHD worldwide, especially among younger populations, despite declining rates in many regions due to better infection control and improved healthcare.
Degenerative changes are the leading cause of valvular disease in the elderly. Calcification of the aortic valve is particularly prevalent, with echo-based studies revealing that approximately 25-30% of individuals aged 65 and older show signs of aortic sclerosis, and a significant subset progress to stenosis. Mitral valve prolapse, often benign, affects roughly 2-3% of the general population and is more common in women. Conversely, rheumatic valvular disease remains a significant health burden in lower-income countries, where access to early diagnosis and treatment is limited, leading to chronic valve damage that may require surgical intervention.
The clinical presentation of valvular heart disease depends largely on the severity and the specific valve involved. Many individuals remain asymptomatic for years, especially in early stages. However, as the disease progresses, symptoms such as fatigue, shortness of breath, palpitations, chest pain, and even syncope can emerge. Left untreated, severe valvular dysfunction may result in heart failure, arrhythmias, or sudden cardiac death. The detection and assessment of VHD rely heavily on echocardiography, which offers a non-invasive means to evaluate valve morphology, function, and the degree of stenosis or regurgitation.
Treatment options have advanced considerably, ranging from medical management to surgical repair or replacement. The decision to intervene depends on symptom severity, the impact on cardiac function, and the risk of complication. For degenerative calcific valves, surgical valve replacement remains the definitive treatment, although less invasive transcatheter procedures have become increasingly popular, especially for high-risk patients.
In conclusion, valvular heart disease is a prevalent condition with a significant impact on public health, especially as populations age. Its varied causes—degenerative, rheumatic, congenital—necessitate accurate diagnosis and timely intervention to prevent adverse outcomes. Continued research and technological advancements promise improved management and prognosis for those affected by VHD across the globe.
